Gepotidacin (BLUJEPA), a first-in-class triazaacenaphthylene antibiotic that inhibits type II bacterial topoisomerases, has been approved in the USA and UK for the treatment of uncomplicated urinary tract infections (uUTIs) in female patients aged 12 years and older weighing at least 40 kg, and in the USA for uncomplicated urogenital gonorrhoea (uUG) in patients aged 12 years and older weighing at least 45 kg who have limited or no alternative treatment options. A new profile published in Drugs & Therapy Perspectives reviews the drug’s evidence base and its place among currently approved antimicrobials.
The approval rests on three pivotal phase 3 trials. In the EAGLE-2 and EAGLE-3 trials in uUTIs, gepotidacin was non-inferior to nitrofurantoin for achieving patient therapeutic responses, defined as combined clinical and microbiological success, and was superior to nitrofurantoin in EAGLE-3. In the EAGLE-1 trial in uUG, gepotidacin was non-inferior to ceftriaxone plus azithromycin in achieving microbiological success.
The therapeutic response measure in the uUTI trials combined symptomatic cure with eradication of the disease-causing bacteria, meaning gepotidacin achieved at least as good, and in one trial better, rates of overall success than the established first-line comparator nitrofurantoin. For uUG, the microbiological success endpoint showed that gepotidacin cleared the causative bacteria at rates at least matching the ceftriaxone plus azithromycin combination.
The arrival of a drug with a novel mechanism of action is significant against a backdrop of rising antimicrobial resistance among the bacteria that cause urinary tract infections and gonorrhoea, a need highlighted in the article’s plain language summary. Because gepotidacin targets type II bacterial topoisomerases through a mechanism distinct from existing antibiotic classes, it represents the first member of a new class of antimicrobials to reach approval for these indications.
Tolerability of gepotidacin was reported as acceptable across the trials, with gastrointestinal events being the most common type of adverse event. Specifically, diarrhoea, nausea and abdominal pain were identified as the most common adverse events in the profile’s summary of the clinical trial data.
The scope of the approvals is deliberately narrow. For uUTIs, gepotidacin is indicated in female adult and paediatric patients aged at least 12 years weighing at least 40 kg. For uUG in the USA, use is restricted to patients aged at least 12 years weighing at least 45 kg who have limited or no alternative treatment options, positioning the drug as an option where existing therapies are unsuitable.
The profile’s authors conclude that gepotidacin is a useful addition to the antimicrobials currently available to treat patients with uUTIs and uUG, offering clinicians an option backed by non-inferiority evidence against established first-line regimens in both indications, and demonstrated superiority over nitrofurantoin in one of the two uUTI trials.
As with any newly approved antimicrobial, the trial evidence summarised here comes from the pivotal phase 3 programme in the specified patient populations, and the profile notes the approved indications and dosing populations precisely as regulators have defined them. Clinicians considering gepotidacin will need to weigh its demonstrated efficacy and acceptable gastrointestinal tolerability profile against the approved patient criteria, which differ between the USA and UK and between the two indications.
Subject of Research: Clinical profile of the novel antibiotic gepotidacin for uncomplicated urinary tract infections and uncomplicated urogenital gonorrhoea
Article Title: Gepotidacin in uncomplicated urinary tract infections and uncomplicated urogenital gonorrhoea: a profile of its use
Article References: Fung, S. (2026). Gepotidacin in uncomplicated urinary tract infections and uncomplicated urogenital gonorrhoea: a profile of its use. Drugs & Therapy Perspectives. https://doi.org/10.1007/s40267-026-01276-3
Image Credits: AI Generated
DOI: 10.1007/s40267-026-01276-3
Keywords: gepotidacin, antibiotics, urinary tract infection, gonorrhoea, antimicrobial resistance, phase 3 trials, EAGLE trials, nitrofurantoin, ceftriaxone, drug approval, BLUJEPA, uncomplicated
News Source: Kristina Jarvis. (October 28, 2026). New antibiotic gepotidacin matches first-line drugs for UTIs and gonorrhoea. Scienmag.
